Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Research & Development (2016 - 2026)

Heron Therapeutics filings provide 15 years of Research & Development readings, the most recent being $2.4 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 4.65% to $2.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.5 million, a 12.67% decrease, with the full-year FY2025 number at $12.4 million, down 25.5% from a year prior.
  • Research & Development hit $2.4 million in Q1 2026 for Heron Therapeutics, down from $3.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $42.1 million in Q1 2022 to a low of -$13.7 million in Q4 2022.
  • Median Research & Development over the past 5 years was $4.5 million (2024), compared with a mean of $9.0 million.
  • Biggest five-year swings in Research & Development: crashed 147.6% in 2022 and later surged 156.76% in 2023.
  • Heron Therapeutics' Research & Development stood at -$13.7 million in 2022, then skyrocketed by 156.76% to $7.8 million in 2023, then crashed by 59.27% to $3.2 million in 2024, then rose by 17.87% to $3.7 million in 2025, then crashed by 36.33% to $2.4 million in 2026.
  • The last three reported values for Research & Development were $2.4 million (Q1 2026), $3.7 million (Q4 2025), and $3.5 million (Q3 2025) per Business Quant data.